Ascites

Clinics in Liver Disease

Volumn 16, Issue 2, 2012, Pages 285-299

  Gordon, Fredric D ^a,b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

Author keywords

Ascites; Cirrhosis; Hepatorenal syndrome; Spontaneous bacterial peritonitis

Indexed keywords

ALBUMIN; ALDOSTERONE; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; AMILORIDE; ANGIOTENSIN II; CEFOTAXIME; CEFTRIAXONE; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; HYDROCHLOROTHIAZIDE; METOLAZONE; MIDODRINE; NONSTEROID ANTIINFLAMMATORY AGENT; NORADRENALIN; NORFLOXACIN; OCTREOTIDE; OFLOXACIN; RENIN; SERUM ALBUMIN; SPIRONOLACTONE; TERLIPRESSIN; VASOPRESSIN;

ALDOSTERONE BLOOD LEVEL; ANTIBIOTIC THERAPY; ARTERY DILATATION; ASCITES; ASCITES FLUID; ASCITES FLUID ANALYSIS; BACTERIAL PERITONITIS; CHYLOUS ASCITES; CONTINUOUS HEMOFILTRATION; CREATININE BLOOD LEVEL; DIURESIS; DIURETIC THERAPY; DRUG DOSE TITRATION; EVENT FREE SURVIVAL; GASTROINTESTINAL HEMORRHAGE; GLOMERULUS FILTRATION RATE; GYNECOMASTIA; HEART OUTPUT; HEMODIALYSIS; HEPATORENAL SYNDROME; HUMAN; HYPOALBUMINEMIA; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; LYMPHANGIOGENESIS; NORADRENALIN BLOOD LEVEL; PARACENTESIS; PATHOPHYSIOLOGY; PERIPHERAL VASCULAR SYSTEM; PERITONEAL CAVITY; PERITONEAL DIALYSIS; PERITONEUM VEIN SHUNT; PLASMA VOLUME; PORTAL HYPERTENSION; PORTOSYSTEMIC ANASTOMOSIS; RECOMMENDED DRUG DOSE; RENAL REPLACEMENT THERAPY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SECONDARY PREVENTION; SODIUM EXCRETION; SODIUM INTAKE; SODIUM RESTRICTION; SODIUM RETENTION; SODIUM URINE LEVEL; SYSTEMIC VASCULAR RESISTANCE; VASOPRESSIN BLOOD LEVEL;

ASCITES; BACTERIAL INFECTIONS; HEPATORENAL SYNDROME; HUMANS; LIVER CIRRHOSIS; PERITONITIS;

EID: 84860294445     PISSN: 10893261     EISSN: 15578224     Source Type: Journal    
DOI: 10.1016/j.cld.2012.03.004     Document Type: Review

References (70)

1. Gines P., Quintero E., Arroyo V., et al. Compensated cirrhosis: the natural history and prognostic factors. Hepatology 1987, 7:122-128.
2. Planas R., Montoliu S., Balleste B., et al. Natural history of patients hospitalized for management of cirrhotic ascites. Clin Gastroenterol Hepatol 2006, 4:1380-1394.
3. Atkinson M., Losowsky M.S. The mechanism of ascites formation in chronic liver disease. Q J Med 1961, 30:153-166.
4. Sherlock A., Shaldon S. The aetiology and management of ascites in patients with hepatic cirrhosis: a review. Gut 1963, 4:95-105.
5. Lieberman F.L., Ito S., Reynolds T.B. Effective plasma volume in cirrhosis with ascites. Evidence that decreased volume does not account for renal sodium retention, a spontaneous reduction in glomerular filtration rate (GFR), and a fall in GFR during drug-induced diuresis. J Clin Invest 1969, 48:975-981.
6. Kostreva D.R., Castaner A., Kampine J.P. Reflex effects of hepatic baroreceptors on renal and cardiac sympathetic nerve activity. Am J Physiol 1980, 238:R390-R394.
7. Liebermann F.L. Overflow theory of ascites formation. Gastroenterology 1989, 96:274.
8. Schroeder E.T., Anderson G.H., Goldman S.H., et al. Effect of blockade of angiotensin II on blood pressure, renin and aldosterone in cirrhosis. Kidney Int 1976, 9:511-519.
9. Arroyo V., Bosch J., Mauri M., et al. Effect of angiotensin-II blockade on systemic and hepatic haemodynamics and on the rennin-angiotensin-aldosterone system in cirrhosis with ascites. Eur J Clin Invest 1981, 11:221-229.
10. Schrier R.W., Arroyo V., Bernardi M., et al. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988, 8:1151-1157.
11. Arroyo V., Gines P., Gerbes A.L., et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology 1996, 23:164-176.
12. Martin P.Y., Gines P., Schrier R.W. Nitric oxide as a mediator of hemodynamic abnormalities in sodium and water retention in cirrhosis. N Engl J Med 1998, 339:533-541.
13. Wattanasirichaigoon S., Gordon F.D., Resnick R.H. Hyperdynamic circulation in portal hypertension: a comparative model of arteriovenous fistula. Med Hypotheses 2000, 55:77-87.
14. Bosch J., Abraldes J.G., Berzigotti D.A., et al. Portal hypertension and gastrointestinal bleeding. Semin Liver Dis 2008, 28:3-25.
15. Iwakiri Y., Groszmann R.J. The hyperdynamic circulation of chronic liver diseases: from the patient to the molecule. Hepatology 2006, 43:S121-S131.
16. Ros J., Claria J., To-Figueras S.J., et al. Endogenous cannabinoids: a new system involved in the homeostasis of arterial pressure and experimental cirrhosis in the rat. Gastroenterology 2002, 122:85-93.
17. MacAllister R.J., Calver A.L., Collier J., et al. Vascular and hormonal responses to arginine: provision of substrate for nitric oxide or nonspecific effect?. Clin Sci 1995, 89:183-190.
18. Cannaziga M., Salerno F., Vistentin S., et al. Increased flow-mediated vasodilation in cirrhotic patients with ascites: relationship with renal resistant index. Liver Int 2008, 28:1396-1401.
19. Korthuis R.J., Kinden D.A., Brimer G.E., et al. Intestinal capillary filtration in acute and chronic portal hypertension. Am J Physiol 1988, 254:G339-G345.
20. Henriksen J.H., Lassen N.A., Parving H.H., et al. Filtration as the main transport mechanism of protein exchange between plasma and the peritoneal cavity and hepatic cirrhosis. Scand J Clin Lab Invest 1980, 40:503-513.
21. Albillos A., de la Hera A., Gonzalez M., et al. Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement. Hepatology 2003, 37:208-217.
22. Frances R., Zapater P., Gonzalez Navajas J.M., et al. Bacterial DNA in patients with cirrhosis and noninfected ascites mimics the soluble immune response established in patients with spontaneous bacterial peritonitis. Hepatology 2008, 47:978-985.
23. Rasaratnam B., Kaye D., Jennings G., et al. The effect of selective intestinal decontamination on the hyperdynamic circulatory state in cirrhosis: a randomized trial. Ann Intern Med 2003, 139:186-193.
24. Arroyo V., Colmenero J. Ascites and have had a renal syndrome in cirrhosis: pathophysiological basis of therapy and current management. J Hepatol 2003, 38:S69-S89.
25. Bosch J., Arroyo V., Betriu A., et al. Hepatic hemodynamics in the renin-angiotensin-aldosterone system in cirrhotics. Gastroenterology 1980, 78:92-99.
26. Bichet D.G., Van Putten V.J., Schrier R.W. Potential role of increased sympathetic activity in impaired sodium and water excretion in cirrhosis. N Engl J Med 1982, 307:1552-1557.
27. Laffi G., La Villa G., Pinzani M., et al. Arachidonic acid derivatives and renal function in liver cirrhosis. Semin Nephrol 1997, 17:530-548.
28. Bataller R., Gines P., Guevara M., et al. have had a renal syndrome. Semin Liver Dis 1997, 17:233-247.
29. Gines A., Escorsell A., Gines P., et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology 1993, 105:229-236.
30. Sanyal A., Boyer T., Garcia-Tsao G., et al. A prospective, randomized, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome (HRS). Gastroenterology 2008, 134:1360-1368.
31. Fabrizi F., Dixit V., Martin P. Meta-analysis: terlipressin therapy for hepatorenal syndrome. Aliment Pharmacol Ther 2006, 24:935-944.
32. Angeli P., Volpin R., Gerunda G., et al. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology 1999, 29:1690-1697.
33. Charlton M.R., Wall W.J., Ojo A.O., et al. international liver transplantation expert panel. Report of the first international liver transplantation Society expert panel consensus conference on renal insufficiency in liver transplantation. Liver Transpl 2009, 15:S1-S34.
34. Brown M.W., Berk R.F. Development of intractable ascites following upper abdominal surgery in patients with cirrhosis. Am J Gastroenterol 1986, 80:879-883.
35. Miedema E.B., Bissada N.K., Finkbeiner, et al. Chylous ascites complicating retroperitoneal lymphadenectomy for testis tumors: management with peritoneovenous shunting. J Urol 1978, 120:377-382.
36. Steinemann D.C., Dindo D., Clavien P.A., et al. Atraumatic chylous ascites: systematic review on symptoms and causes. J Am Coll Surg 2011, 212:899-905.
37. Rector W.G. Spontaneous chylous ascites of cirrhosis. J Clin Gastroenterol 1984, 6:369-372.
38. Hammond T.C., Takiyyuddin M.A. Nephrogenic ascites: a poorly understood syndrome. J Am Soc Nephrol 1994, 5:1173-1177.
39. Guarner C., Runyon B.A. Spontaneous bacterial peritonitis: pathogenesis, diagnosis, and management. Gastroenterologist 1995, 3:311-328.
40. Runyon B.A. Paracentesis of ascitic fluid: a safe procedure. Arch Intern Med 1986, 146:2259-2261.
41. Runyon B.A. Management of adult patients with ascites caused by cirrhosis. Hepatology 1998, 27:264-272.
42. Grabau C.M., Crago S.F., Hoff L.K., et al. Performance standards for therapeutic abdominal paracentesis. Hepatology 2004, 40:484-488.
43. Runyon B.A., AASLD practice guidelines management of adult patients with ascites due to cirrhosis: an update. Hepatology 2009, 49:2087-2107.
44. Yu A.S., Hu K.Q. Management of ascites. Clinics in liver disease: current and future treatment therapies for liver disease 2001, 541-568. WB Saunders Company, Philadelphia. R.G. Gish (Ed.).
45. Leung W., Wong F. Medical management of ascites. Expert Opin Pharmacother 2011, 12:1269-1283.
46. Angeli P., Della Pria M., De Bei E., et al. randomized clinical study of the efficacy of amiloride and potassium canrenoate in nonazotemic cirrhotic patients with ascites. Hepatology 1994, 19:72-79.
47. Shear L., Ching S., Gabuzda G.J. Compartmentalization of ascites and edema in patients with hepatic cirrhosis. N Engl J Med 1970, 282:1391-1396.
48. Pinto-Marques P., Vieira A. Urinary sodium/potassium ratio on random sample as a useful tool to assess diuretic induced natriuresis on chronic liver disease-associated ascites. Am J Gastroenterol 2007, 102:212-213.
49. Romanelli R.G., La Villa G., Barletta G., et al. Long-term albumin infusion improves survival in patients with cirrhosis and ascites: an unblinded randomized trial. World J Gastroenterol 2006, 12:1403-1407.
50. Crenshaw W.B., Gordon F.D., McEniff N.J., et al. Severe ascites: efficacy of the transjugular intrahepatic portosystemic shunt in treatment. Radiology 1996, 200:185-192.
51. Haynes G.R., Navickis R.J., Wilkes M.M. Albumin administration - what is the evidence of clinical benefit? a systematic review of randomized controlled trials. Eur J Anaesthesiol 2003, 20:771-793.
52. European Association for the Study of the Liver EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol 2010, 53:397-417.
53. Rossle M., Ochs A., Gulberg V., et al. A comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascites. N Engl J Med 2000, 342:1701-1707.
54. Gines P., Uriz J., Calahorra B., et al. Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. Gastroenterology 2002, 123:1839-1847.
55. Sanyal A.J., Genning C., Reddy R.K., et al. The North American study for the treatment of refractory ascites. Gastroenterology 2003, 124:634-641.
56. Salerno F., Merli M., Riggio O., et al. Randomized controlled study of TIPS vs. paracentesis plus albumin in cirrhosis with severe ascites. Hepatology 2004, 40:629-635.
57. Wong F., Bernardi M., Balk R., et al. Sepsis in cirrhosis: report on the seventh meeting of the International Ascites Club. Gut 2005, 54:718-725.
58. Tandon P., Garcai-Tsao G. Bacterial infections, sepsis, and multiorgan failure in cirrhosis. Semin Liver Dis 2008, 28:26-42.
59. Navasa M., Follo A., Llovet J.M., et al. Randomized, comparative study of oral ofloxacin versus intravenous cefotaxime in spontaneous bacterial peritonitis. Gastroenterology 1996, 111:1011-1017.
60. Sort P., Navasa M., Arroyo V., et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999, 341:403-409.
61. Sigal S.H., Stanca C.M., Fernandez J., et al. Restricted use of albumin for spontaneous bacterial peritonitis. Gut 2007, 56:597-599.
62. Garcia-Tsao G. current management of complications of cirrhosis and portal hypertension: variceal hemorrhage, ascites, and spontaneous bacterial peritonitis. Gastroenterology 2001, 120:726-748.
63. Gines P., Rimola A., Planas R., et al. Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial. Hepatology 1990, 12:716-724.
64. Rolachon A., Cordier L., Bacq Y., et al. ciprofloxacin and long-term prevention of spontaneous bacterial peritonitis: results of a prospective controlled trial. Hepatology 1995, 22:1171-1174.
65. Singh N., Gayowski T., Yu V.L., et al. Trimethoprim-sulfamethoxazole for the prevention of spontaneous bacterial peritonitis in cirrhosis: a randomized trial. Ann Intern Med 1995, 122:595-598.
66. Novella M., Sola R., Soriano G., et al. Continuous versus inpatient prophylaxis of the first episode of spontaneous bacterial peritonitis with norfloxacin. Hepatology 1997, 25:532-536.
67. Fernandez J., Navasa M., Planas R., et al. Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology 2007, 133:818-824.
68. Grange J.D., Roulot D., Pelletier G., et al. Norfloxacin primary prophylaxis of infections in patients with ascites: a double-blind randomized trial. J Hepatol 1998, 29:430-436.
69. Terg R., Fassio E., Guevara M., et al. Ciprofloxacin in primary prophylaxis of spontaneous bacterial peritonitis: a randomized, placebo-controlled study. J Hepatol 2008, 48:774-779.
70. Fernandez J., Ruiz del Arbol L., Gomez C., et al. Norfloxacin vs ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and hemorrhage. Gastroenterology 2006, 131:1049-1105.